Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Complutense University of Madrid, Spain; Pharmaceutical Innovation in Ophthalmology Research Group, Sanitary Research Institute of the San Carlos Clinical Hospital (IdISSC) and the Ocular Pathology National Net (OFTARED) of the Institute of Health Carlos III, Madrid, Spain.
DSM, 6167 AC Geleen, The Netherlands.
J Control Release. 2015 Aug 10;211:105-17. doi: 10.1016/j.jconrel.2015.05.279. Epub 2015 May 21.
Most of the posterior segment diseases are chronic and multifactorial and require long-term intraocular medication. Conventional treatments of these pathologies consist of successive intraocular injections, which are associated with adverse effects. Successful therapy requires the development of new drug delivery systems able to release the active substance for a long term with a single administration. The present work involves the description of a new generation of microspheres based on poly(ester amide)s (PEA), which are novel polymers with improved biodegradability, processability and good thermal and mechanical properties. We report on the preparation of the PEA polymer, PEA microspheres (PEA Ms) and their characterization. PEA Ms (~15μm) were loaded with a lipophilic drug (dexamethasone) (181.0±2.4μg DX/mg Ms). The in vitro release profile of the drug showed a constant delivery for at least 90days. Based on the data from a performed in vitro release study, a kinetic ocular model to predict in vivo drug concentrations in a rabbit vitreous was built. According to the pharmacokinetic simulations, intravitreal injection of dexamethasone loaded PEA microspheres would provide release of the drug in rabbit eyes up to 3months. Cytotoxicity studies in macrophages and retinal pigment epithelial cells revealed a good in vitro tolerance of the microsystems. After sterilization, PEA Ms were administered in vivo by subtenon and intravitreal injections in male Sprague-Dawley rats and the location of the microspheres in rat eyes was monitored. We conclude that PEA Ms provide an alternative delivery system for controlling the delivery of drugs to the eye, allowing a novel generation of microsphere design.
大多数后节疾病是慢性和多因素的,需要长期的眼内药物治疗。这些病变的传统治疗方法包括连续的眼内注射,这与不良反应有关。成功的治疗需要开发新的药物输送系统,能够在单次给药时以长期方式释放活性物质。本工作涉及基于聚(酯酰胺)(PEA)的新一代微球的描述,这是具有改善的生物降解性、可加工性和良好的热和机械性能的新型聚合物。我们报告了 PEA 聚合物、PEA 微球(PEA Ms)及其特性的制备。PEA Ms(约 15μm)负载疏水性药物(地塞米松)(181.0±2.4μg DX/mg Ms)。药物的体外释放曲线显示至少 90 天内持续释放。根据进行的体外释放研究数据,建立了预测兔玻璃体内药物浓度的动力学眼模型。根据药代动力学模拟,地塞米松负载 PEA 微球的玻璃体内注射将在兔眼内提供长达 3 个月的药物释放。巨噬细胞和视网膜色素上皮细胞的细胞毒性研究表明微系统具有良好的体外耐受性。微球经灭菌后,通过腱下和玻璃体内注射将 PEA Ms 体内给药,监测微球在大鼠眼中的位置。我们得出结论,PEA Ms 为控制药物向眼睛的输送提供了替代的输送系统,允许新一代微球设计。